Erratum to: Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults &#8805;50 Years of Age.

Chlibek, Roman; Bayas, José M; Collins, Harry; de la Pinta, Maria Luisa Rodriguez; Ledent, Edouard; Mols, Johann F; Heineman, Thomas C

Erratum to: Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults ≥50 Years of Age.

Chlibek, Roman; Bayas, José M; Collins, Harry; de la Pinta, Maria Luisa Rodriguez; Ledent, Edouard; Mols, Johann F; Heineman, Thomas C.

Afiliação

Chlibek R; Department of Epidemiology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
Bayas JM; Centro de Vacunación de Adultos, Servicio de Medicina Preventiva y Epidemiología, Hospital Clínic, Barcelona, Spain.
Collins H; Anderson & Collins Clinical Research, Inc, Edison, New Jersey.
de la Pinta MLR; Occupational Risk Prevention Department, Puerta de Hierro Hospital, Madrid, Spain.
Ledent E; GlaxoSmithKline Vaccines, Rixensart, Belgium.
Mols JF; GlaxoSmithKline Vaccines, Rixensart, Belgium.
Heineman TC; GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania.

J Infect Dis ; 223(2): 353, 2021 02 03.

Article em En | MEDLINE | ID: mdl-33215671

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Infect Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: República Tcheca